{"DataElement":{"publicId":"8070680","version":"1","preferredName":"Target Lesion Response ITMIG MRECIST Criteria Type","preferredDefinition":"Text term to represent disease response in a target lesion using the ITMIG MRECIST criteria.","longName":"LES_ITMIG_MRECIST_TP","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"2188858","version":"1","preferredName":"Target Lesion Response","preferredDefinition":"Information relating to target lesion response.","longName":"TARGET_LES_RESP","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2206598","version":"1","preferredName":"Target Lesion","preferredDefinition":"The goal intended to be attained.:(LEE-zhun) An area of abnormal tissue change.","longName":"C25702:C3824","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Target","conceptCode":"C25702","definition":"An object fixed as a goal or point of examination; something to point at; a destination.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-FBAD-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177336","version":"1","preferredName":"Response","preferredDefinition":"Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","longName":"Response","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-528C-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":"Denise Warzel updated Definition by seraching NCI Thesaurus in Admin tool.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"irRECIST: Immune-related Response Evaluation Criteria in Solid Tumours (RECIST)-2013","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E49C180D-8CF4-0916-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-10-05","modifiedBy":"SOKKERL","dateModified":"2017-10-19","changeDescription":"8/31/17 tt transferred context, added registration status and CSI per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"8070675","version":"1","preferredName":"ITMIG MRECIST Benveniste Thymic Epithelial Tumors 2014 Oncology Response Criteria Type","preferredDefinition":"A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria. (Marcelo F Benveniste, Robert J Korst, Arun Rajan, Frank C Detterbeck, Edith M Marom, International Thymic Malignancy Interest Group. A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria. J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S119-24.)_Something distinguishable as an identifiable class based on common qualities.","longName":"ITMIG_MRECIST_RSP_TY","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stable Disease (SD)","valueDescription":"ITMIG MRECIST Stable Disease","ValueMeaning":{"publicId":"8070676","version":"1","preferredName":"ITMIG MRECIST Stable Disease","longName":"8070676","preferredDefinition":"Neither sufficient shrinkage to qualify for partial response nor sufficient growth to qualify for progressive disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ITMIG MRECIST Stable Disease","conceptCode":"C185857","definition":"Neither sufficient shrinkage to qualify for partial response nor sufficient growth to qualify for progressive disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D96832E7-CAA5-5D87-E053-4EBD850A9AEB","latestVersionIndicator":"Yes","beginDate":"2022-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D96832E7-CABE-5D87-E053-4EBD850A9AEB","beginDate":"2022-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"Progressive Disease (PD)","valueDescription":"ITMIG MRECIST Progressive Disease","ValueMeaning":{"publicId":"8070677","version":"1","preferredName":"ITMIG MRECIST Progressive Disease","longName":"8070677","preferredDefinition":"Greater than or equal to 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters in the study.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ITMIG MRECIST Progressive Disease","conceptCode":"C185856","definition":"Greater than or equal to 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters in the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D96832E7-CACA-5D87-E053-4EBD850A9AEB","latestVersionIndicator":"Yes","beginDate":"2022-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D96832E7-CAE3-5D87-E053-4EBD850A9AEB","beginDate":"2022-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"Partial Response (PR)","valueDescription":"ITMIG MRECIST Partial Response","ValueMeaning":{"publicId":"8070678","version":"1","preferredName":"ITMIG MRECIST Partial Response","longName":"8070678","preferredDefinition":"Greater than or equal to 30% decrease in the sum of the diameters of up to five target lesions as compared to baseline sum of diameters.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ITMIG MRECIST Partial Response","conceptCode":"C185855","definition":"Greater than or equal to 30% decrease in the sum of the diameters of up to five target lesions as compared to baseline sum of diameters.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D96832E7-CAEF-5D87-E053-4EBD850A9AEB","latestVersionIndicator":"Yes","beginDate":"2022-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D96832E7-CB08-5D87-E053-4EBD850A9AEB","beginDate":"2022-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"},{"value":"Complete Response (CR)","valueDescription":"ITMIG MRECIST Complete Response","ValueMeaning":{"publicId":"8070679","version":"1","preferredName":"ITMIG MRECIST Complete Response","longName":"8070679","preferredDefinition":"Disappearance of all target lesions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ITMIG MRECIST Complete Response","conceptCode":"C185854","definition":"Disappearance of all target lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D96832E7-CB14-5D87-E053-4EBD850A9AEB","latestVersionIndicator":"Yes","beginDate":"2022-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D96832E7-CB2D-5D87-E053-4EBD850A9AEB","beginDate":"2022-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"8070674","version":"1","preferredName":"ITMIG MRECIST Benveniste Thymic Epithelial Tumors 2014 Oncology Response Criteria Type","preferredDefinition":"A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria. (Marcelo F Benveniste, Robert J Korst, Arun Rajan, Frank C Detterbeck, Edith M Marom, International Thymic Malignancy Interest Group. A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria. J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S119-24.):Something distinguishable as an identifiable class based on common qualities.","longName":"C179780:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ITMIG MRECIST Benveniste Thymic Epithelial Tumors 2014 Oncology Response Criteria","conceptCode":"C179780","definition":"A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria. (Marcelo F Benveniste, Robert J Korst, Arun Rajan, Frank C Detterbeck, Edith M Marom, International Thymic Malignancy Interest Group. A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria. J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S119-24.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D96832E7-CA7D-5D87-E053-4EBD850A9AEB","latestVersionIndicator":"Yes","beginDate":"2022-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-04","modifiedBy":"ONEDATA","dateModified":"2022-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D96832E7-CA8E-5D87-E053-4EBD850A9AEB","latestVersionIndicator":"Yes","beginDate":"2022-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-04","modifiedBy":"KUMMEROA","dateModified":"2022-03-04","changeDescription":"2022-3-4 ak Created for CCR.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"International Thymic Malignan","type":"Preferred Question Text","description":"International Thymic Malignancy Interest Group (ITMIG) modified RECIST criteria Tumor Response","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9685735-0966-249A-E053-4EBD850A19ED","latestVersionIndicator":"Yes","beginDate":"2022-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-04","modifiedBy":"KUMMEROA","dateModified":"2022-03-04","changeDescription":"2022-3-4 ak Created for CCR.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}